PRTK — Paratek Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $127.83m
- $343.47m
- $160.27m
Brief: Paratek Pharmaceuticals Announces Initiation Of Phase 2B Study In Nontuberculous Mycobacterial Pulmonary Disease
Brief: Paratek Appoints Minnie Baylor-Henry To Company’S Board Of Directors
Brief: Paratek Pharmaceuticals Announces FDA Approval Of Nuzyra (Omadacycline) Oral Only Dosing Regimen For The Treatment Of Community-Acquired Bacterial Pneumonia (Cabp)
Paratek Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Paratek Pharmaceuticals - May Offer, Sell Shares Of Common Stock Having Offering Price Of Up To $50 Mln From Time To Time
Brief: Paratek Pharmaceuticals - Q1 Revenue Rose 107% To $16.4 Mln
Paratek Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Paratek Pharmaceuticals Reports Full Year 2020 Total Rev Of $46.9 Mln
Brief: Paratek Receives $60 Million Non-Recourse Loan From R-Bridge Healthcare Investment Advisory
Brief: Paratek Says Co Through Unit Entered Royalty And Revenue Interest-Backed Loan Agreement
Brief: Paratek Pharmaceuticals Posts Q3 Loss Per Share $0.46
Brief: Paratek Pharmaceuticals Reports Q2 Loss Per Share $0.53
U.S. STOCKS ON THE MOVE-Cellect Biotechnology, Quidel, AMC Entertainment
Brief: Paratek Pharmaceuticals Reports Q1 2020 Total Revenues Of $7.9 Million
Brief: Paratek Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln – SEC Filing
Paratek Pharmaceuticals rises after co reports surge in Q1 revenue
Brief: Paratek Pharmaceuticals Announces Initiation Of Funding From Barda For All FDA Required Post-Marketing Studies For Nuzyra
Brief: Paratek Pharmaceuticals Announces Initiation Of Funding From Barda For Security Requirements And U.S. Onshoring Of The Manufacturing Supply Chain For Nuzyra
Brief: Paratek Announces License Grant To Almirall For Seysara For Greater China Region